Sanofi/Regeneron COPD Trial Shows 27% Benefit in AERIFY-1 but Fails in AERIFY-2
Sanofi and Regeneron’s itepekimab delivered 27.1% and 20.5% reductions in moderate-severe COPD exacerbations in AERIFY-1, but AERIFY-2 showed non-significant 12.4% and 1.6% reductions. The trial inconsistency and 17–18% severe adverse event rates could complicate FDA approval prospects.
1. Phase III Data Recap
The AERIFY-1 and AERIFY-2 trials enrolled former smokers with moderate to severe COPD, testing itepekimab at 300mg every two or four weeks. AERIFY-1 showed statistically significant exacerbation rate reductions of 27.1% (q2w) and 20.5% (q4w), whereas AERIFY-2 reported attenuated and non-significant reductions of 1.6% (q2w) and 12.4% (q4w).
2. Implications for FDA Approval
Regulators typically require consistent positive results from replicate trials, so AERIFY-2’s failure to reach significance threatens the therapy’s approval pathway. With severe treatment-emergent adverse events averaging 17–18%, Sanofi and Regeneron may need additional data or new studies to satisfy FDA efficacy and safety standards.
3. Competitive Landscape
AstraZeneca’s anti-IL-33 antibody tozorakimab recently achieved primary endpoint success in two Phase III COPD trials, reducing exacerbations across former and current smokers. This consistent performance positions tozorakimab as a leading contender in the COPD market, narrowing itepekimab’s potential market share and commercial prospects.